The EMJ Podcast: Insights For Healthcare Professionals

Majid Fotuhi joins host Saranya Ravindran to explore how nutrition influences brain ageing. From anti-inflammatory diets and omega-3s to insulin resistance and metabolic health, this episode unpacks how what we eat shapes cognition and long-term brain resilience.  Timestamps:  01:10 – Mediterranean Diet  02:58 – Reducing Alzheimer's risk  03:37 – Dietary changes  05:44 – Metabolic dysfunction  08:00 – Exercise and Sleep 

In this rapid-fire episode, Majid Fotuhi answers key questions on brain ageing - from memory-boosting habits and diet to stress, neurogenesis, and Alzheimer's risk. Perfect for a quick, science-backed overview of how to protect your brain. 

This content has been funded by AstraZeneca, and is intended for healthcare professionals. The content in this podcast is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment, nor to promote any specific product or therapy.  The guests have been compensated by AstraZeneca for their participation. The views expressed are their own and do not necessarily reflect those of the AMJ or AstraZeneca. If you choose to act on information discussed here, you do so at your own discretion. Description: As homologous recombination deficiency (HRD) testing becomes increasingly embedded in ovarian cancer pathways, clinicians need clear, operational guidance. This episode brings together expert perspectives on selecting tests, understanding outputs, and integrating results into guideline-aligned care.  Learn: ·       HRD basics in plain language: what you're measuring and why ·       Test selection and reporting nuances that affect downstream decisions ·       Workflow design across oncology, pathology, and genetics ·       Applying results to maintenance strategies and patient conversations  Speakers: 1.     Rebecca Arend, Associate Director for Clinical Research, UAB O'Neal Comprehensive Cancer Center; Endowed Professor of Gynecologic Oncology, University of Alabama, USA. 2.   Thomas Krivak, Director, Division of Gynecologic Oncology; Chief Surgeon, West Penn Hospital, USA. 3.    Bhavana Pothuri, Gynecologic Oncologist, NYU Langone Health; Associate Professor, Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, USA.

Järvinen-Seppo discusses how translational research is advancing understanding of early allergic disease, from maternal antibodies to global collaborations shaping the future of prevention and care. Timestamps: 00:57 – Research scope  03:49 – Maternal antibodies  07:34 – Integrating new evidence  09:17 – International coordination  10:37 – Emerging areas

This episode examines the spectrum of food allergy, from IgE-mediated disease to food protein induced enterocolitis syndrome and eosinophilic conditions, and explores how diet, skin barrier function, and the microbiome interact in early life. Timestamps: 00:53 – Spectrum of allergic diseases 05:00 – Nutrition and immune activation 07:22 – Atopic dermatitis 08:55 – IgE-mediated food allergy 10:28 – Future management pathways

In this episode of Onc Now, Claire Snyder explores the growing importance of patient-reported outcomes and quality of life in modern oncology care. She discusses the challenges and opportunities of integrating patient perspectives into routine practice, as well as the global effort to standardise these measures through initiatives such as the PROTEUS Consortium. The conversation also highlights the evolving needs of survivors of cancer, key priorities in survivorship care, and what the future holds for patient-centred oncology.  Timestamps:   00:00 – Introduction   01:41 – Modern oncology care  03:56 – Patient-reported outcomes (PRO) interest origin   05:10 - PRO implementation challenges   06:36 - PROTEUS Consortium mission   08:33 - Survivorship care priorities   09:45 - Childhood survivor insights   12:35 - Advice for newcomers   13:37 - Future quality of life developments   14:41 - Three wishes 

Kirsi Järvinen-Seppo explores how the infant immune system develops, highlighting the role of maternal environment, breast milk composition, and early-life exposures in shaping allergy risk. Timestamps: 00:57 – Infant immune system 02:06 – Maternal lifestyle factors 06:10 – Breast milk composition 10:13 – ESCAPE study 13:25 – Early sensitisation pathways 16:58 – Early risk stratification

In this rapid-fire episode, Kirsi Järvinen-Seppo tackles key questions on infant immune development, common misconceptions around food allergy, and the early-life factors that shape allergic disease. She also highlights emerging research on maternal influences, breast milk immunology, and prevention strategies that could transform clinical practice.

In the final deep dive, Cherry Lim looks ahead to the future of AMR surveillance. She discusses the role of microbiology labs, the value of imperfect datasets, and how integrating genomics, modelling, and cost-effectiveness could transform global health systems over the next two decades. Timestamps 00:00 – Introduction 01:03 – Investing in diagnostics 02:36 – Routine surveillance data 03:53 – Global versus local AMR data 05:08 – Future health systems

In this second deep dive episode, Cherry Lim discusses how complex modelling approaches can translate into practical clinical insights. From counterfactual frameworks to real-world prescribing decisions, she explores how data-driven tools can support clinicians in choosing more effective antibiotic treatments.  Timestamps 00:00 – Introduction 01:03 – Understanding counterfactual frameworks 02:56 – Antibiotic choice and survival 05:08 – Clinical decision dashboards 06:24 – Assumptions in AMR modelling

In this episode of Hema Now, Marilyn Manco-Johnson explores the evolution and future of paediatric haemophilia care. From the early adoption of prophylactic treatment to today's rapidly advancing therapeutic landscape, she reflects on the milestones that have transformed outcomes for children. The conversation also dives into ongoing challenges, including joint health, variability in treatment response, and access to care, while highlighting emerging innovations such as gene therapy and non-factor therapies that could redefine long-term management.  Timestamps:   00:00 – Introduction   00:49 - Career inspiration   04:40 - Prophylaxis turning points   09:41 - Key care advances   12:12 - Current research questions   15:00 - Joint risk factors   19:10 - Emerging therapies impact   24:24 – Recognising joint pain   26:08 - Gaps in care   29:11 - Future priorities  

In this first deep dive, Lim explores how routine hospital data and bacterial genomics are transforming our understanding of AMR. She explains how combining datasets and transmission models can uncover hidden pathways of resistance and highlights the challenges of working across diverse healthcare settings.

Cherry Lim joins the EMJ Podcast for a rapid-fire discussion on data, modelling, and antimicrobial resistance. From surveillance gaps to the role of AI, she shares insights into how data is shaping the future of AMR research and policy.

Monga reflects on global urology practice, prevention challenges, and equity in care delivery. This episode explores how stone management adapts across healthcare systems and what needs to change to improve outcomes worldwide. Timestamps: 00:00 – Global experience 02:20 – Resource adaptation 05:00 – Public health challenges 07:40 – Equity in urology 10:30 – Future advice

From device development to real-world surgical impact, Manoj Monga discusses how innovation is transforming stone management. This episode covers emerging technologies, procedural advances, and the future of minimally invasive care. Timestamps: 00:00 – Innovation pipeline 02:40 – Device development 05:30 – Surgical advances 08:10 – Technology trends 10:50 – Improving outcomes

In this episode of Onc Now, Patricia Ganz sits down with EMJ to explore the evolving field of cancer survivorship. From managing long-term treatment effects to improving transitions into post-treatment care, she highlights key gaps in research, the growing role of patient-reported outcomes, and the importance of integrating policy, advocacy, and clinical practice to better support survivors.  Timestamps: 00:00 – Introduction   01:24 - Career survivorship inspiration  03:10 - Survivorship field evolution   04:10 - Late effects challenges   06:40 - Post-treatment care transition   07:58 - Patient-reported outcomes impact   10:14 - Advocacy policy research intersection   13:29 - Advice for new researchers   15:07 – Bench to beside challenges  17:40 – Equipping younger clinicians   19:16 - Future survivorship innovations   20:14 - Three survivorship wishes  

The following podcasts were funded by Edgewise Therapeutics. Disclaimers: The views and opinions expressed in these podcasts are those of the individual speakers and do not necessarily reflect those of Edgewise Therapeutics or EMJ. The speakers received honoraria for participating in this recording. Becker muscular dystrophy (Becker) affects more than just motor function. This episode features Elias Bracamonte, an individual living with Becker, and Gloria Bracamonte, his wife and a Becker patient advocate. Through sharing their story, they dive into the quality of life impacts of Becker on patients and their loved ones.

Manoj Monga explores the evolving understanding of kidney stone pathophysiology, from metabolic drivers to recurrence risk. This episode unpacks how clinicians balance acute intervention with long-term prevention strategies. Timestamps: 00:00 – Monga's background 02:30 – Pathophysiology explained 05:10 – Recurrence risk factors 08:20 – Dietary management 11:00 – Prevention versus surgery

In this rapid-fire episode, Manoj Monga tackles common myths about kidney stones, shares clinical preferences, and highlights key innovations shaping modern endourology. A concise, high-yield overview of the field.

What is the science behind early allergen introduction? In Part 2, Debbie Palmer explains the immunological basis of oral tolerance, addresses persistent myths, and outlines best practices for introducing allergens, especially in high-risk infants. Timestamps: 00:56 – Allergen introduction 02:03 – Non-breastfeeding approaches 02:54 – Biggest myth 03:49 – Tolerance versus sensitisation 04:48 – High-risk patients 05:25 – Weaning diet 06:49 – Prohibited foods

In this episode of Hema Now, Karina Yazdanbakhsh speaks about her journey into immunology, the challenges of alloimmunisation, and the evolving landscape of transfusion medicine. She also reflects on receiving the prestigious Henry M. Stratton Medal for Basic Research at ASH 2025 and what this recognition means for her work. The conversation explores key insights from ASH 2025, highlights pressing immunological issues in sickle cell disease, and looks ahead to emerging technologies shaping personalised transfusion strategies.  Timestamps:   00:00 – Introduction   00:59 - Stratton Medal meaning  02:19 - ASH 2025 highlights  13:11 - Sickle cell challenges  17:00 - Immune tolerance evolution  18:55 - Institute research priorities  27:20 - Novel therapeutics role  29:04 - Early career advice  29:43 - Emerging technologies impact  32:30 – Three magic wishes for healthcare  

In this episode, Satish Raj and Gert van Dijk explore the diagnosis, clinical burden, and management of orthostatic hypotension. The discussion examines how low blood pressure affects daily functioning, the importance of accurate diagnosis, and current treatment approaches.  Key Discussion Themes Definitions and subtypes of orthostatic hypotension Differential diagnosis and the role of tilt-table testing  Impact on quality of life and daily functioning  Current treatment landscape and clinical guidelines  Unmet needs and future research priorities 

In this episode, Aaron Phillips discusses haemodynamic instability following spinal cord injury, with particular focus on autonomic dysreflexia. The conversation reviews the neuronal mechanisms underpinning autonomic dysfunction, the clinical burden of hypertensive and hypotensive complications, and current management strategies. The episode also explores emerging therapeutic approaches, including the development and evaluation of implantable systems designed to restore haemodynamic stability.  Key Discussion Themes  Definition and clinical features of haemodynamic instability  Autonomic dysreflexia: mechanisms and patient impact  Chronic hypertensive and hypotensive complications 

In the final episode of the series, David Goldstein examines orthostatic hypotension as a manifestation of autonomic failure in Parkinson's disease. The discussion explores the pathophysiology of cardiac noradrenergic deficiency, its identification and clinical implications, and current management approaches. The episode also considers the prognostic significance of orthostatic hypotension in Parkinson's disease and potential future directions in research and patient care.  Key Discussion Themes  Autonomic failure in Parkinson's disease  Cardiac noradrenergic deficiency: definition and identification  Clinical consequences, including falls and cognitive impairment  Mechanistic insights into sympathetic denervation  Current treatment approaches and guideline considerations  Future research priorities 

Debbie Palmer joins host Catherine Glass to explore how maternal diet shapes fetal immune development and influences allergy risk. This episode unpacks key nutrients, timing of dietary exposures, and findings from randomised trials that challenge conventional pregnancy nutrition advice.  Timestamps:  01:22 – Maternal diet  02:59 – Mid-pregnancy versus preconception  03:53 – Food groups  04:28 – Prebiotic supplements  05:30 – Pregnancy cravings 

In this rapid-fire episode, Debbie Palmer answers key questions on allergy prevention, from pregnancy nutrition myths and early allergen introduction to common misconceptions among clinicians and parents. A concise overview of cutting-edge thinking in just a few minutes. 

This episode has been funded by Sun Pharmaceutical Industries, Inc. Please see full Prescribing Information and the Patient Information for clascoterone cream 1%. Sebum plays a central role in acne pathogenesis. In this AMJ Rapid Review, Zoe Diana Draelos, MD, breaks down what new 52-week findings with clascoterone cream 1% may mean for everyday dermatology practice. In under 15 minutes, learn: How did the study objectively measure sebum, and what makes that approach clinically useful? What did the 52-week results reveal about changes over time, beyond what you see in the first few visits? How might sebum trends relate to standard acne assessments in longer-term follow-up? What practical expectations and counseling tips can help patients stay on track with treatment?  Speaker: Zoe Diana Draelos, MD Dermatology Consulting Services, PLLC, North Carolina, USA   IMPORTANT SAFETY INFORMATION Indication What is WINLEVI cream? WINLEVI (clascoterone) cream 1% is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older. It is not known if WINLEVI cream is safe and effective in children under 12 years of age. Important Patient Information Before using WINLEVI cream, tell your healthcare provider about all of your medical conditions, particularly if you: have skin problems, including eczema, cuts or sunburn are pregnant or plan to become pregnant. It is not known if WINLEVI cream will harm your unborn baby are breastfeeding or plan to breastfeed. It is not known if WINLEVI cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with WINLEVI cream WINLEVI cream is for use on the skin only (topical). Do not use WINLEVI cream in or on your eyes, mouth, or vagina. Do not use WINLEVI cream for a condition for which it was not prescribed. Do not give WINLEVI cream to other people, even if they have the same symptoms you have. It may harm them. What are the possible side effects of WINLEVI cream? WINLEVI cream can cause serious side effects, including: local skin reactions. WINLEVI cream may cause local skin irritation including itching, burning, skin redness or peeling. symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment with WINLEVI. Your healthcare provider may stop your treatment with WINLEVI if you develop any adrenal problems. The most common side effects of WINLEVI cream include reddening, scaling or dryness, and itching of the skin being treated. These are not all of the possible side effects of WINLEVI cream. Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Sun Pharmaceutical Industries, Inc. by calling 1-800-818-4555. Please see full Prescribing Information and the Patient Information.

In this first deep dive, Leslie Cho explores how lipidology and hormone therapy intersect in women's cardiovascular care. Drawing on major guideline work and trial data, she explains how clinicians should approach menopausal hormone therapy, complex lipid disorders, microvascular disease, and emerging therapies through a precision lens.  Timestamps:  01:10 – Menopausal hormone therapy  03:45 – Lipid-lowering therapy  05:55 – Microvascular disease  07:55 – Testosterone therapy 

In this rapid-fire episode, Leslie Cho answers essential questions on women's cardiovascular health, from overlooked risk factors and lipid values to myths about chest pain, microvascular disease, menopause, and the future of precision cardiology.

In the final deep dive, Matteo Bassetti discusses antimicrobial resistance beyond the bedside: translating evidence into policy, the importance of national surveillance, lessons from sepsis and COVID-19, and the future of antibiotic innovation and hospital preparedness. Timestamps: 01:24 – Translating evidence into policy 02:54 – National surveillance 04:15 – Sepsis and COVID-19 06:18 – Investment shortfalls 08:41 – Antibiotic crisis 10:19 – Looking ahead

In the second deep dive, Matteo Bassetti examines antibiotic stewardship where policy meets practice. He highlights gaps between guidelines and bedside realities, practical interventions for limited-resource settings, and balancing preservation of new antibiotics with effective treatment today. Timestamps: 01:27 – Guideline gaps 04:40 – Encouraging stewardship 06:23 – Realistic interventions 09:59 – Antibiotic shortages 11:16 – Preserving new drugs

In this episode of Hema Now, Ana Boban discusses her vision as the incoming EAHAD President for 2026–2028. From her early experiences in haemophilia care to her leadership in European clinical trials and guideline development, she reflects on the future of bleeding disorders in Europe, highlighting the importance of supporting young clinicians and researchers, advancing clinical practice, and driving innovation in haemophilia care and research.  Timestamps:   00:00 – Introduction   01:38 - Vision for EAHAD Presidency  03:50 - Building on Past Leadership  06:45 - Key Priorities: Practice, Research, Education  09:05 - EAHAD Congress Highlights  11:20 - European Haemophilia Landscape Today  14:17 - Advances Influencing Clinical Care  16:14 - Unmet Needs in Europe  17:45 - Supporting Young Clinicians, Researchers  20:00 - Long-Term Goals Beyond 2028  TBC- Three Wishes for Haemophilia

1.      In this first deep dive, Bassetti discusses the changing landscape of antimicrobial resistance in hospitals and ICUs, the challenges of multidrug-resistant Gram-negative bacteria, and the vulnerability of patients who are critically ill and immunocompromised. He explores how diagnosis, empiric therapy, and therapeutic monitoring influence outcomes and resistance. Timestamps: 01:09 – Antimicrobial resistance trends 04:06 – Tackling sepsis 06:39 – Gram-negative threat 08:15 – Vulnerable populations 10:00 – Diagnosis and empiric therapy 12:14 – Dosing and pharmacokinetics 14:32 – Antibiotic allergies

Matteo Bassetti joins the EMJ Podcast for a rapid-fire discussion on antimicrobial resistance in hospitals. From prescribing pitfalls to early versus precise antibiotic use, he shares insights on howantimicrobial resistance is impacting real-world clinical care.

Drawing on her landmark work in HIV and vaccine research, Glenda Gray shares powerful lessons for tackling AMR in this last deep dive episode. From prevention and behavioural science to protecting high-risk populations, she explains how strategies that transformed HIV outcomes can inform a more effective and equitable AMR response. Timestamps: 00:00 – Introduction 01:02 – Lessons from HIV 02:47 – Vaccine trials 03:50 – AMR interventions 05:17 – Behavioural science 06:31 – Key takeaways

In this second deep dive, Glenda Gray examines why the global antibiotic pipeline is failing and how access gaps are fuelling resistance. She discusses GARDP's mission-driven research and development model, the neglect of paediatric antibiotics, and how shortages of first-line treatments drive reliance on last-resort drugs, worsening the antimicrobial resistance crisis. Timestamps: 00:00 – Introduction 00:58 – Antibiotic development 03:05 – GARDP's model 04:15 – Paediatric antibiotics 04:58 – Antibiotic shortages 05:50 – Access gaps

In this episode of Onc Now, Michael Cecchini, Associate Professor of Medicine at Yale School of Medicine, New Haven, Connecticut, USA, discusses his journey into gastrointestinal oncology and the evolution of care for patients with colorectal and rectal cancers. From the complexities of multidisciplinary coordination to the promise of early-phase clinical trials, Cecchini reflects on how molecular profiling and next-generation systemic therapies are reshaping treatment paradigms.  Timestamps:   00:00 – Introduction   01:13 – Path to gastrointestinal oncology  03:00 – Multidisciplinary care challenges  07:20 – Early phase trial advances  11:26 – Evolving systemic therapies  14:58 – Impact of molecular profiling  20:20 – Translating trials to practice  23:38 – Advice for clinician investigators  28:21 – Future therapeutic advances  31:50 – Three wishes for gastrointestinal care 

In this first deep dive, Glenda Gray unpacks what antimicrobial resistance means for clinicians beyond infectious diseases, and why it is already a leading cause of death globally. She explores the disproportionate burden in low- and middle-income countries, the devastating impact on neonates and infants, and the critical role of diagnostics, vaccines, and infection prevention. Timestamps: 00:00 – Introduction 00:45 – What is AMR? 01:32 – Burden on LMICs  02:57 – Impact on infants 04:05 – Diagnostic gaps 05:10 – Comprehensive strategies

Glenda Gray joins the EMJ Podcast for a quickfire discussion on antimicrobial resistance and child health. From antibiotic misconceptions to equitable access and stewardship, she shares sharp insights into why AMR is a defining global health challenge for children today.

Description: The final deep dive episode looks ahead: stem cells, tissue transplantation, fertility preservation in cancer care, and the policy challenges limiting access to advanced male infertility treatment. A future-facing discussion on cures and equity. Timestamps: 00:00 – Introduction 01:02 – Stem cells 04:08 – Fertility preservation 05:04 – Access and cost 07:04 – Pricing variability 08:20 – What's next?

Description: In this second deep dive, Schlegel explains how microTESE transformed sperm retrieval. Learn how microsurgical precision improves outcomes, preserves testicular tissue, reduces pain, and why multidisciplinary collaboration drives high pregnancy rates. Timestamps:00:00 – Introduction 01:06 – Why the microscope? 03:09 – MicroTESE advantages 04:11 – Success rates 06:29 – Postoperative care 08:04 – Multidisciplinary approaches

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

Description: In this first deep dive, Peter N. Schlegel joins host Catherine Glass to unpack non-obstructive azoospermia. Explore genetic discoveries, hormonal optimisation, age-related factors, and practical strategies that maximise sperm retrieval and conception potential. Timestamps: 00:00 – Introduction 01:13 – Non-obstructive azoospermia 02:01 – Genetics of infertility 04:01 – Aromatase inhibitors 06:05 – Sperm quality 07:27 – Multiple semen samples 10:27 – Infertility globally

In this rapid-fire episode, Peter N. Schlegel answers key questions about male infertility, from what drives success in microTESE to the role of genetics, hormones, and surgical skill. A concise introduction to the science shaping modern men's reproductive care.

Bairey Merz discusses the latest directions in microvascular and endothelial research, including links to heart failure with preserved ejection fraction, integration of adverse pregnancy outcomes and autoimmune disease into models, and promising technological advances. Timestamps: 00:53 – Directions of the WISE programme 01:47 – Preserved ejection fraction 04:51 – Adverse outcomes of microvascular disease 08:42 – Technology improving outcomes

This episode examines how diagnostic tools and imaging for microvascular dysfunction are evolving, the paradox of 'clear' arteries in symptomatic women, and barriers to broader implementation in clinical practice. Timestamps: 00:45 – Angina in women 03:43 – Defining ischaemia 05:35 – Barriers to microvascular testing

In this episode of Onc Now, Kevin Harrington discusses the evolving landscape of head and neck cancer treatment, from the transformative impact of immunotherapy to the promise of oncolytic viruses. He reflects on the challenges that defined a decade of limited progress, the integration of radiotherapy and systemic therapies, and the importance of translating innovative science into clinical benefit. With insights into salivary gland cancers, combination strategies, and advice for the next generation of oncologists, this episode offers a comprehensive look at one of oncology's most rapidly advancing fields.  Timestamps:  00:00 – Introduction  01:10 – Specialisation in head and neck cancers  03:39 – Biggest challenges   06:30 – Impact of radiotherapy   11:19 – Role of systemic therapy  16:13 – Immunotherapy   21:10 – Salivary gland cancers  28:34 – Viruses as anti-cancer agents  33:22 – Translating innovative science  38:00 – Pairing viruses for certain cancers  41:47 – Advice to young oncologists  44:29 – Important breakthroughs  47:21 – Three magic wishes 

Bairey Merz explores the science of microvascular dysfunction in women, the role of the WISE initiative, and how these findings have redefined diagnosis, preventive cardiology, and symptom assessment. Timestamps: 01:04 – Barbra Streisand Women's Heart Center 03:35 – WISE initiative 06:36 – Microvascular angina 11:11 – Preventative cardiology

Noel Bairey Merz answers rapid-fire questions on women's heart health, including misconceptions about angina, key insights from the WISE study, and emerging imaging technologies.

In the final episode, Vidur Mahajan looks ahead to the future of radiology. From AI-enabled education to convergence with genomics and pathology, this discussion explores how imaging and AI will reshape diagnostics over the next decade.   Timestamps:  00:00 – Introduction  00:51 – Exciting innovations  03:47 – Role of radiologists  05:59 – AI and education  08:40 – AI and genomics  10:55 – What's next?